High-dose methotrexate in adults with osteosarcoma: A population pharmacokinetics study and validation of a new limited sampling strategy

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 267-273

  Dupuis, Charlotte ^a   Mercier, Cedric ^a   Yang, Chenguang ^a   Monjanel Mouterde, Suzanne ^a   Ciccolini, Joseph ^a   Fanciullino, Raphaelle ^a   Pourroy, Bertrand ^a   Deville, Jean Laurent ^a   Duffaud, Florence ^a   Bagarry Liegey, Danielle ^a   Durand, Alain ^a   Iliadis, Athanassios ^a   Favre, Roger ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Bayesian estimation; High dose methotrexate; Leucovorin rescue; Osteosarcoma; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE; CREATININE;

ACCURACY; ADULT; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; BODY SURFACE; CANCER PATIENT; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MALE; OSTEOSARCOMA; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; VALIDATION PROCESS; ADOLESCENT; BIOLOGICAL MODEL; BLOOD; COST BENEFIT ANALYSIS; FORECASTING; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; TIME; URINE; VALIDATION STUDY;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; BAYES THEOREM; BODY SURFACE AREA; COST-BENEFIT ANALYSIS; CREATININE; DRUG MONITORING; FEMALE; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 45549085928     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f21376     Document Type: Article

References (30)

1. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43:2163-2177.
2. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2:617-624.
3. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004; 100:1724-1733.
4. Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L. Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer 2004; 42:52-58.
5. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16:658-663.
6. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12:1443-1451.
7. Borsi JD, Schuler D, Moe PJ. Methotrexate administered by 6 and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol 1988; 22:33-35.
8. Delepine N, Desbois JC, Delepine G, Cornille H, Astier A, Alkallaf S. Individualization of the dosage of high-dose methotrexate by assaying plasma concentration. Therapeutic value in osteogenic sarcoma. Bull Cancer 1989; 76:913-918.
9. Delepine N, Delepine G, Desbois JC. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery. Cancer Treat Res 1993; 62:327-332.
10. Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Lo S, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005; 44: 638-642.
11. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33:420-424.
12. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84:452-459.
13. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221-1230.
14. Monjanel-Mouterde S, Lejeune C, Ciccolini J, Merite N, Hadjaj D, Bonnier P, et al. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. J Clin Pharm Ther 2002; 27:189-195.
15. Iliadis A, Brown AC, Huggins ML. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 1992; 38: 227-239.
16. Bruno R, Iliadis A, Favre R, Lena N, Imbert AM, Cano JP. Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance. Cancer Drug Deliv 1985; 2:277-283.
17. Karlsson MO, Beal SL, Sheiner LB. Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm 1995; 23: 651-672.
18. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic- pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20:511-528.
19. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11:303-319.
20. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.
21. Bacci G, Loro L, Longhi A, Bertoni F, Bacchini P, Versari M, et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 2006; 17:411-415.
22. Ciccolini J, Monjanel-Mouterde S, Bun SS, Blanc C, Duffaud F, Favre R, et al. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit 2002; 24:709-714.
23. Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, et al. Dose individualization of carboplatin after a 120-h infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 2006; 28:212-218.
24. Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, et al. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006; 28:532-539.
25. Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 2002; 13:327-330.
26. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, et al. Areas under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90:353-358.
27. Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33: 164-169.
28. Fabre G, Fabre I, Matherly LH, Cano JP, Goldman ID. Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem 1984; 259:5066-5072.
29. Evans WE, Relling MV, Boyett JM, Pui CH. Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? Leuk Res 1997; 21:435-437.
30. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-1672.